Takeda's ixazomib meets PFS endpoint in myeloma study

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said an interim analysis of the Phase III TOURMALINE-MM1 trial showed ixazomib ( MLN9708) met the primary endpoint of increasing PFS in patients with relapsed or refractory multiple myeloma (MM). The company did not disclose detailed data or provide a timeline for regulatory submissions. Takeda said full results will be presented at a future medical meeting.

The orally available proteasome inhibitor has Orphan Drug designation in the U.S. and EU for MM. ...